In May 2006, you published a review 'Research misconduct: poisoning the well' by former editor of the British Medical Journal Richard Smith 1 in which the problem of identifying scientific fraud was discussed and a general failure to develop methods for examination of possible cases was noted. He stated that, unlike many other countries, the Nordic countries had developed processes yet chose to highlight a case from Norway in which he, as editor of the BMJ, had successfully asked an author's employer to investigate. That investigation at the University of Oslo found that 'there was not a problem with the work'. The paper by Norwegian general practitioner Dr Grethe Støa Birketvedt was published in the BMJ 2 with a 'sceptical' commentary from Professor John Garrow. 3 The matter might have rested there had Dr Smith not added 'I am not sure if the work was fraudulent, but I am left with severe doubts' in his 2006 JRSM article, 13 years after the first misconduct investigation in Oslo. This damaging comment published in the JRSM and repeated in Dr Smith's book has led to professional difficulties for the investigator formerly under suspicion and ultimately led to a re-examination of the case all over again, this time by the ethical committee of the University of Tromsø where she had received a PhD in 1995 [JF was the supervisor, ARL was the principal external examiner]. In August 2009, the University of Tromsø announced that, following a very thorough enquiry into the issue, the Research Ethics Committee concluded that allegations of scientific misconduct were unfounded [including an identity confirmation from University Director, University of Tromsø], 4 yet no effort has been made to publicize this finding of 'not guilty'.
While we support every effort to identify cases of fraud and withdraw papers presenting fraudulent claims, we feel that scientific journals have an equally strong moral obligation to make a clear statement when a suspect investigator has been found not guilty.
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The disappointment of the double helix: a master theory
The article by James Le Fanu 1 brings to attention the huge discrepancy between the unalloyed promise of great medical benefits from unravelling the human genome and the meagre practical benefits so far achieved.
The fundamental flaw in the 'Human Genome Project' is that it has been forgotten that genes do not exist by themselves but are embedded in a biological and terrestrial milieu called the 'environment'. The attempt to provide monogenic explanation for common diseases is thus mistaken.
The problem can be illustrated by the case of ankylosing spondylitis (AS), where 96% of the patients possess HLA-B27 while it is present in only 8% of the general population. 2 Although some 10-20% of HLA-B27 positive individuals have some features of AS (backache, muscle stiffness), the majority are symptom-free.
Molecular mimicry between the gene product and environmental bowel bacteria, such as Klebsiella, provides a simple explanation which has therapeutic implications. Antibodies to Klebsiella have been found in AS patients from 14 different countries, 3 yet expensive tricontinental studies do not provide an explanation for the high frequency of HLA-B27 in this disease.
A similar situation occurs in rheumatoid arthritis (RA), where some 90% of patients possess the 'shared epitope' (EQRRAA) found in HLA-DR1/4 molecules while it is present in only onethird of the general population. 4 Molecular mimicry between the 'shared epitope' and the sequence ESRRAL found in Proteus haemolysin indicates that RA is associated with a common microbe. 5 An analysis using 'Popper sequences' clearly shows that genes linked to RA require the intervention of an environmental factor, namely an upper urinary tract infection by Proteus bacteria. 6 The rationale for expensive, multicentre genome studies in common diseases would appear to require some critical discussion and revision.
Flight plans, patient safety and American hospitals -is it time to check the baggage of private sector oversight?
A recent JRSM paper 1 compared efforts to improve healthcare quality with various aspects of the aviation industry. Although there are similarities between the airline industry and surgery, key differences also exist in exchange of safety data, particularly in the United States.
At institutional levels, the National Transportation Safety Board publishes detailed reports on air crashes investigated in USA. But reports and recommendations concerning inspected American hospitals are the property of private certifying groups like the Joint Commission. That crucial information is kept secret; it is left to the hospital to decide what, if anything, is disclosed to the general public.
At the individual level, the most junior team member in the cockpit can advise and correct a senior pilot. 1 When aviation safety problems go beyond the cockpit, a US government programme legally shields the whistleblower from any retaliation. 2 Yet, a hospital staff member who reports a breach of hospital policy in good faith can find their own safety complaint simply handed over to the hospital and used against them in a civil trial. 3 Since hospital accreditation remains the exclusive province of the private sector, the 'best hospitals in America' can turn out to be most any hospital that can pay for a Joint Commission site survey. 4 There is no parallel to this in the aviation industry.
Vigilant and unbiased monitoring of institutional quality systems by public forums and meaningful certification has become a hallmark of aviation safety. The Institute of Medicine (USA) estimates that over 90,000 patient fatalities occur every year from preventable medical error -the equivalent of a catastrophic jumbo jet crash each day. 5 As quality management structures are compared across hospital surgery and aviation, increased transparency in US hospital inspection and accreditation processes would be a welcome step to address this problem.
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